Alexandros Tzatsos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alexandros Tzatsos has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Jaclyn Andricovich
Department of Anatomy and Cell Biology The George Washington University School of Medicine and Health Sciences Washington DC USA
6 shared publications - Weiqun Peng
Department of Physics, The George Washington University, Washington DC, USA
4 shared publications - Yan Kai
Predictive Sciences, Bristol Myers Squibb, San Diego, California
4 shared publications Jaclyn Andricovich
George Washington University, Washington, District of Columbia, UNITED STATES
3 shared publicationsYan Kai
Cancer Epigenetics Laboratory, Department of Anatomy and Cell Biology, GWU School of Medicine and Health Sciences, Washington, DC, 20052, USA
2 shared publications- Adlen Foudi
Inserm UMR 1310, Campus CNRS, université Paris-Saclay, Villejuif, France
1 shared publication
Latest Publications
- 20 June 2025
- Published by American Society of Hematology in Blood
Loss of BAP1 defines a unique subtype of TP53-mutated de novo AML and confers sensitivity to BCL-xL inhibitors
Mutations in TP53 are mutually exclusive with other known drivers of myeloid transformation and define a distinct molecular subtype within de novo Acute Myeloid Leukemia (AML) that is associated with a complex karyotype, resistance to chemotherapy, and poor prognosis. Although TP53 defects are rare in de novo AML, biallelic mutations are a defining molecular feature of erythroleukemia. The genetic alterations that cooperate with defective TP53 to transform erythroid progenitors remain unknown. We found that loss of BAP1 (BRCA1 Associated Protein-1) co-occurs in one-third of patients with TP53-mutated AML, is associated with an erythroid-primed gene expression signature, and confers an additional adverse effect on overall survival. BAP1 is a tumor suppressor involved in the DNA damage response as well as epigenetic regulation through histone H2AK119 de-ubiquitination. While Bap1KO mice develop myelodysplasia with prominent dyserythropoiesis, combined deletion of Bap1 and Trp53 caused transplantable erythroleukemia, and occasionally mixed AML, mirroring the heterogeneity of human disease. Bulk and single-cell RNA-seq coupled to ChIP-seq in hematopoietic progenitors revealed that Bap1 loss triggers a proinflammatory response and cooperates with Trp53 deficiency to transform erythroid-primed multipotent progenitors. Mechanistically, genomic instability led to the development of erythroleukemia, while epigenetic deregulation caused myelomonocytic skewing suggesting a dichotomous and context dependent role for BAP1. We also demonstrate that BAP1 deficient erythroleukemia is dependent on BCL2L1 expression and is sensitive to BCL-xL inhibitors in vivo.
- 20 June 2025
- Published by American Society of Hematology in Blood
Loss of BAP1 defines a unique subtype of TP53-mutated de novo AML and confers sensitivity to BCL-xL inhibitors
Mutations in TP53 are mutually exclusive with other known drivers of myeloid transformation and define a distinct molecular subtype within de novo Acute Myeloid Leukemia (AML) that is associated with a complex karyotype, resistance to chemotherapy, and poor prognosis. Although TP53 defects are rare in de novo AML, biallelic mutations are a defining molecular feature of erythroleukemia. The genetic alterations that cooperate with defective TP53 to transform erythroid progenitors remain unknown. We found that loss of BAP1 (BRCA1 Associated Protein-1) co-occurs in one-third of patients with TP53-mutated AML, is associated with an erythroid-primed gene expression signature, and confers an additional adverse effect on overall survival. BAP1 is a tumor suppressor involved in the DNA damage response as well as epigenetic regulation through histone H2AK119 de-ubiquitination. While Bap1KO mice develop myelodysplasia with prominent dyserythropoiesis, combined deletion of Bap1 and Trp53 caused transplantable erythroleukemia, and occasionally mixed AML, mirroring the heterogeneity of human disease. Bulk and single-cell RNA-seq coupled to ChIP-seq in hematopoietic progenitors revealed that Bap1 loss triggers a proinflammatory response and cooperates with Trp53 deficiency to transform erythroid-primed multipotent progenitors. Mechanistically, genomic instability led to the development of erythroleukemia, while epigenetic deregulation caused myelomonocytic skewing suggesting a dichotomous and context dependent role for BAP1. We also demonstrate that BAP1 deficient erythroleukemia is dependent on BCL2L1 expression and is sensitive to BCL-xL inhibitors in vivo.
- 27 September 2023
- Published by Springer Nature
- Vol. 1433, 51-68
Biological Functions of the KDM2 Family of Histone Demethylases
The histone lysine demethylase 2 (KDM2) family of α-Ketoglutarate-Fe++-dependent dioxygenases were the first Jumonji-domain-containing proteins reported to harbor demethylase activity. This landmark discovery paved the way for the characterization of more than 25 enzymes capable of demethylating lysine residues on histones—an epigenetic modification previously thought to be irreversible. The KDM2 family is comprised of KDM2A and KDM2B which share significant structural similarities and demethylate lysine 36 on histone H3. However, they exert distinct cellular functions and are frequently deregulated in a broad spectrum of human cancers. With the advent of next generation sequencing and development of genetically engineered mouse models, it was shown that KDM2A and KDM2B play critical roles in stem cell biology, somatic cell reprograming, and organismal development by regulating cell fate and lineage commitment decisions. Thus, understanding the biochemistry and elucidating the context-dependent function of these enzymes is an emerging new frontier for the development of small molecule inhibitors to treat cancer and other diseases. Keywords KDM2A KDM2B Jumonji Histone demethylase Cancer Leukemia Pancreatic cancer DNA methylation Histone modification
- 27 September 2023
- Published by Springer Nature
- Vol. 1433, 51-68
Biological Functions of the KDM2 Family of Histone Demethylases
The histone lysine demethylase 2 (KDM2) family of α-Ketoglutarate-Fe++-dependent dioxygenases were the first Jumonji-domain-containing proteins reported to harbor demethylase activity. This landmark discovery paved the way for the characterization of more than 25 enzymes capable of demethylating lysine residues on histones—an epigenetic modification previously thought to be irreversible. The KDM2 family is comprised of KDM2A and KDM2B which share significant structural similarities and demethylate lysine 36 on histone H3. However, they exert distinct cellular functions and are frequently deregulated in a broad spectrum of human cancers. With the advent of next generation sequencing and development of genetically engineered mouse models, it was shown that KDM2A and KDM2B play critical roles in stem cell biology, somatic cell reprograming, and organismal development by regulating cell fate and lineage commitment decisions. Thus, understanding the biochemistry and elucidating the context-dependent function of these enzymes is an emerging new frontier for the development of small molecule inhibitors to treat cancer and other diseases. Keywords KDM2A KDM2B Jumonji Histone demethylase Cancer Leukemia Pancreatic cancer DNA methylation Histone modification
- Open Access
- 1 November 2021
- Published by Elsevier in Cell Reports
- Vol. 37 (8) , 110036
Differentiation of fetal hematopoietic stem cells requires ARID4B to restrict autocrine KITLG/KIT-Src signaling
- 1 November 2021
- Published by Elsevier in Cell Reports
- Vol. 37 (8) , 110036
Open AccessDifferentiation of fetal hematopoietic stem cells requires ARID4B to restrict autocrine KITLG/KIT-Src signaling
- Open Access
- 15 June 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-17
BAP1 is a haploinsufficient tumor suppressor linking chronic pancreatitis to pancreatic cancer in mice
Chronic pancreatitis represents a risk factor for the development of pancreatic cancer. We find that heterozygous loss of histone H2A lysine 119 deubiquitinase BAP1 (BRCA1 Associated Protein-1) associates with a history of chronic pancreatitis and occurs in 25% of pancreatic ductal adenocarcinomas and 40% of acinar cell carcinomas. Deletion or heterozygous loss of Bap1 in murine pancreata causes genomic instability, tissue damage, and pancreatitis with full penetrance. Concomitant expression of KrasG12D leads to predominantly intraductal papillary mucinous neoplasms and mucinous cystic neoplasms, while pancreatic intraepithelial neoplasias are rarely detected. These lesions progress to metastatic pancreatic cancer with high frequency. Lesions with histological features mimicking Acinar Cell Carcinomas are also observed in some tumors. Heterozygous mice also develop pancreatic cancer suggesting a haploinsufficient tumor suppressor role for BAP1. Mechanistically, BAP1 regulates genomic stability, in a catalytic independent manner, and its loss confers sensitivity to irradiation and platinum-based chemotherapy in pancreatic cancer.
- 15 June 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-17
Open AccessBAP1 is a haploinsufficient tumor suppressor linking chronic pancreatitis to pancreatic cancer in mice
Chronic pancreatitis represents a risk factor for the development of pancreatic cancer. We find that heterozygous loss of histone H2A lysine 119 deubiquitinase BAP1 (BRCA1 Associated Protein-1) associates with a history of chronic pancreatitis and occurs in 25% of pancreatic ductal adenocarcinomas and 40% of acinar cell carcinomas. Deletion or heterozygous loss of Bap1 in murine pancreata causes genomic instability, tissue damage, and pancreatitis with full penetrance. Concomitant expression of KrasG12D leads to predominantly intraductal papillary mucinous neoplasms and mucinous cystic neoplasms, while pancreatic intraepithelial neoplasias are rarely detected. These lesions progress to metastatic pancreatic cancer with high frequency. Lesions with histological features mimicking Acinar Cell Carcinomas are also observed in some tumors. Heterozygous mice also develop pancreatic cancer suggesting a haploinsufficient tumor suppressor role for BAP1. Mechanistically, BAP1 regulates genomic stability, in a catalytic independent manner, and its loss confers sensitivity to irradiation and platinum-based chemotherapy in pancreatic cancer.
- 19 December 2019
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 4 (24)
Secretome profiling identifies neuron-derived neurotrophic factor as a tumor-suppressive factor in lung cancer
Clinical and preclinical studies show tissue-specific differences in tumorigenesis. Tissue specificity is controlled by differential gene expression. We prioritized genes that encode secreted proteins according to their preferential expression in normal lungs to identify candidates associated with lung cancer. Indeed, most of the lung-enriched genes identified in our analysis have known or suspected roles in lung cancer. We focused on the gene encoding neuron-derived neurotrophic factor ( NDNF ), which had not yet been associated with lung cancer. We determined that NDNF was preferentially expressed in the normal adult lung and that its expression was decreased in human lung adenocarcinoma and a mouse model of this cancer. Higher expression of NDNF was associated with better clinical outcome of patients with lung adenocarcinoma. Purified NDNF inhibited proliferation of lung cancer cells, whereas silencing NDNF promoted tumor cell growth in culture and in xenograft models. We determined that NDNF is downregulated through DNA hypermethylation near CpG island shores in human lung adenocarcinoma. Furthermore, the lung cancer–related DNA hypermethylation sites corresponded to the methylation sites that occurred in tissues with low NDNF expression. Thus, by analyzing the tissue-specific secretome, we identified a tumor-suppressive factor, NDNF, which is associated with patient outcomes in lung adenocarcinoma.
- 19 December 2019
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 4 (24)
Secretome profiling identifies neuron-derived neurotrophic factor as a tumor-suppressive factor in lung cancer
Clinical and preclinical studies show tissue-specific differences in tumorigenesis. Tissue specificity is controlled by differential gene expression. We prioritized genes that encode secreted proteins according to their preferential expression in normal lungs to identify candidates associated with lung cancer. Indeed, most of the lung-enriched genes identified in our analysis have known or suspected roles in lung cancer. We focused on the gene encoding neuron-derived neurotrophic factor ( NDNF ), which had not yet been associated with lung cancer. We determined that NDNF was preferentially expressed in the normal adult lung and that its expression was decreased in human lung adenocarcinoma and a mouse model of this cancer. Higher expression of NDNF was associated with better clinical outcome of patients with lung adenocarcinoma. Purified NDNF inhibited proliferation of lung cancer cells, whereas silencing NDNF promoted tumor cell growth in culture and in xenograft models. We determined that NDNF is downregulated through DNA hypermethylation near CpG island shores in human lung adenocarcinoma. Furthermore, the lung cancer–related DNA hypermethylation sites corresponded to the methylation sites that occurred in tissues with low NDNF expression. Thus, by analyzing the tissue-specific secretome, we identified a tumor-suppressive factor, NDNF, which is associated with patient outcomes in lung adenocarcinoma.
- Open Access
- 11 October 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 1-14
Predicting CTCF-mediated chromatin interactions by integrating genomic and epigenomic features
The CCCTC-binding zinc-finger protein (CTCF)-mediated network of long-range chromatin interactions is important for genome organization and function. Although this network has been considered largely invariant, we find that it exhibits extensive cell-type-specific interactions that contribute to cell identity. Here, we present Lollipop, a machine-learning framework, which predicts CTCF-mediated long-range interactions using genomic and epigenomic features. Using ChIA-PET data as benchmark, we demonstrate that Lollipop accurately predicts CTCF-mediated chromatin interactions both within and across cell types, and outperforms other methods based only on CTCF motif orientation. Predictions are confirmed computationally and experimentally by Chromatin Conformation Capture (3C). Moreover, our approach identifies other determinants of CTCF-mediated chromatin wiring, such as gene expression within the loops. Our study contributes to a better understanding about the underlying principles of CTCF-mediated chromatin interactions and their impact on gene expression.
- 11 October 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 1-14
Open AccessPredicting CTCF-mediated chromatin interactions by integrating genomic and epigenomic features
The CCCTC-binding zinc-finger protein (CTCF)-mediated network of long-range chromatin interactions is important for genome organization and function. Although this network has been considered largely invariant, we find that it exhibits extensive cell-type-specific interactions that contribute to cell identity. Here, we present Lollipop, a machine-learning framework, which predicts CTCF-mediated long-range interactions using genomic and epigenomic features. Using ChIA-PET data as benchmark, we demonstrate that Lollipop accurately predicts CTCF-mediated chromatin interactions both within and across cell types, and outperforms other methods based only on CTCF motif orientation. Predictions are confirmed computationally and experimentally by Chromatin Conformation Capture (3C). Moreover, our approach identifies other determinants of CTCF-mediated chromatin wiring, such as gene expression within the loops. Our study contributes to a better understanding about the underlying principles of CTCF-mediated chromatin interactions and their impact on gene expression.
- 22 June 2018
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 20 (suppl_2) , i59
DIPG-50. CHROMATIN IMMUNOPRECIPITATION OF DIFFUSE INTRINSIC PONTINE GLIOMA TUMOR TISSUE IS FEASIBLE AND SHOW DIFFERENT ENRICHMENT COMPARED TO PRIMARY CELL LINE
Diffuse intrinsic pontine glioma (DIPG) is the leading cause of mortality in pediatric central nervous system cancers. Histone mutations are found in >80% of DIPG cases. The most common mutation is histone 3.3 at position 27 resulting in lysine to methionine(H3.3K27M). This mutation results in epigenetic changes in methylation and acetylation of histones leading to aberrant change in transcription globally. Analysis of epigenetic changes via chromatin immunoprecipitation followed by sequencing (ChIP-Seq) has been performed in DIPG cell lines but not in tumor tissue. Culture conditions may not accurately reflect the epigenome of the tumor, thus we performed ChIP on three H3.3K27M mutant DIPG tumors (PID675, PID693, PID874). Checking enrichment by PCR revealed that the HOXA gene was enriched by tri-methylation at K27 (K27me3) and TOP3A was enriched by acetylation at K27 (K27ac), as expected. There was enrichment in both K27me3 and K27ac for GLI2. CDKN2A was enriched in K27me3 indicating down regulation in tumor tissue. However, in the DIPG primary cell line derived from PID675, CDKN2A was not enriched in K27me3 or K27ac and GLI2 was only enriched in K27ac. Given the difference seen between tumor tissue and cell line, our findings highlight the crucial importance of profiling the actual tumor tissue in DIPG.
- 22 June 2018
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 20 (suppl_2) , i59
DIPG-50. CHROMATIN IMMUNOPRECIPITATION OF DIFFUSE INTRINSIC PONTINE GLIOMA TUMOR TISSUE IS FEASIBLE AND SHOW DIFFERENT ENRICHMENT COMPARED TO PRIMARY CELL LINE
Diffuse intrinsic pontine glioma (DIPG) is the leading cause of mortality in pediatric central nervous system cancers. Histone mutations are found in >80% of DIPG cases. The most common mutation is histone 3.3 at position 27 resulting in lysine to methionine(H3.3K27M). This mutation results in epigenetic changes in methylation and acetylation of histones leading to aberrant change in transcription globally. Analysis of epigenetic changes via chromatin immunoprecipitation followed by sequencing (ChIP-Seq) has been performed in DIPG cell lines but not in tumor tissue. Culture conditions may not accurately reflect the epigenome of the tumor, thus we performed ChIP on three H3.3K27M mutant DIPG tumors (PID675, PID693, PID874). Checking enrichment by PCR revealed that the HOXA gene was enriched by tri-methylation at K27 (K27me3) and TOP3A was enriched by acetylation at K27 (K27ac), as expected. There was enrichment in both K27me3 and K27ac for GLI2. CDKN2A was enriched in K27me3 indicating down regulation in tumor tissue. However, in the DIPG primary cell line derived from PID675, CDKN2A was not enriched in K27me3 or K27ac and GLI2 was only enriched in K27ac. Given the difference seen between tumor tissue and cell line, our findings highlight the crucial importance of profiling the actual tumor tissue in DIPG.
- Top Cited Papers
- 1 March 2018
- Published by Elsevier in Cancer Cell
- Vol. 33 (3) , 512-526.e8
Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors
- 1 March 2018
- Published by Elsevier in Cancer Cell
- Vol. 33 (3) , 512-526.e8
Top Cited PapersLoss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors
- 1 September 2016
- Published by Elsevier in Experimental Hematology
- Vol. 44 (9) , 778-782
Lysine-specific histone demethylases in normal and malignant hematopoiesis
- 1 September 2016
- Published by Elsevier in Experimental Hematology
- Vol. 44 (9) , 778-782
Lysine-specific histone demethylases in normal and malignant hematopoiesis
- Open Access
- 25 January 2016
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 126 (3) , 905-920
Histone demethylase KDM2B regulates lineage commitment in normal and malignant hematopoiesis
The development of the hematopoietic system is a dynamic process that is controlled by the interplay between transcriptional and epigenetic networks to determine cellular identity. These networks are critical for lineage specification and are frequently dysregulated in leukemias. Here, we identified histone demethylase KDM2B as a critical regulator of definitive hematopoiesis and lineage commitment of murine hematopoietic stem and progenitor cells (HSPCs). RNA sequencing of Kdm2b-null HSPCs and genome-wide ChIP studies in human leukemias revealed that KDM2B cooperates with polycomb and trithorax complexes to regulate differentiation, lineage choice, cytokine signaling, and cell cycle. Furthermore, we demonstrated that KDM2B exhibits a dichotomous role in hematopoietic malignancies. Specifically, we determined that KDM2B maintains lymphoid leukemias, but restrains RAS-driven myeloid transformation. Our study reveals that KDM2B is an important mediator of hematopoietic cell development and has opposing roles in tumor progression that are dependent on cellular context.
- 25 January 2016
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 126 (3) , 905-920
Open AccessHistone demethylase KDM2B regulates lineage commitment in normal and malignant hematopoiesis
The development of the hematopoietic system is a dynamic process that is controlled by the interplay between transcriptional and epigenetic networks to determine cellular identity. These networks are critical for lineage specification and are frequently dysregulated in leukemias. Here, we identified histone demethylase KDM2B as a critical regulator of definitive hematopoiesis and lineage commitment of murine hematopoietic stem and progenitor cells (HSPCs). RNA sequencing of Kdm2b-null HSPCs and genome-wide ChIP studies in human leukemias revealed that KDM2B cooperates with polycomb and trithorax complexes to regulate differentiation, lineage choice, cytokine signaling, and cell cycle. Furthermore, we demonstrated that KDM2B exhibits a dichotomous role in hematopoietic malignancies. Specifically, we determined that KDM2B maintains lymphoid leukemias, but restrains RAS-driven myeloid transformation. Our study reveals that KDM2B is an important mediator of hematopoietic cell development and has opposing roles in tumor progression that are dependent on cellular context.